all report title image
  • Published In : Apr 2023
  • Code : CMI2824
  • Pages : 170
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.

Market Dynamics

Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.

Moreover, in January 2021, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.

Key features of the study:

  • This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bipolar disorder treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

  • Global Anti-Obesity Drug Market, By Mechanism of Action:
    • Peripherally Acting Anti-Obesity Drugs
    • Centrally Acting Anti-Obesity Drugs
  • Global Anti-Obesity Drug Market, By Prescription/Non- prescription:
    • Prescription Drugs
    • OTC Drugs
  • Global Anti-Obesity Drug Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • VIVUS Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer, Inc.
    • Novo Nordisk
    • Bayer AG
    • F Hoffmann-La Roche
    • Glaxosmithkline
    • Arena Pharmaceuticals
    • Eisai Co. Ltd.
    • Takeda Pharmaceutical Company
    • Nalpropion Pharmaceuticals Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Mechanism of Action
      • Market Snapshot, By Prescription/Non- prescription
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product Launch
    • Technological Advancements
    • PEST Analysis
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Anti-Obesity Drug Market- Impact of Coronavirus (Covid-19) Pandemic
    •  Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Anti-Obesity Drug Market, By Mechanism of Action, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Peripherally Acting Anti-Obesity Drugs  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Centrally Acting Anti-obesity Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Anti-Obesity Drug Market, By Prescription/Non- prescription, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Prescription Drugs  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • OTC Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Anti-Obesity Drug Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Mechanism of Action, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Prescription/Non- prescription, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • VIVUS Inc. *
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novo Nordisk
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bayer AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F Hoffmann-La Roche
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Glaxosmithkline
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Arena Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eisai Co. Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Takeda Pharmaceutical Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Nalpropion Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  9. Section
    • Research Methodology
    • About Us

*Browse 35 market data tables and 34 figures on “Global Anti-Obesity Drug Market” - Global forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo